Exploring metabolic dysfunction in chronic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Cardiology

Background:

• Chronic kidney disease (CKD) significantly elevates risks for cardiovascular disease (CVD), mortality, and morbidity.
• CKD is characterized by physiological and metabolic disturbances like hypertension, dyslipidemia, and anorexia-cachexia syndrome, contributing to poor patient outcomes.

Purpose of the Study:

• To explore the multifaceted hormonal, inflammatory, and nutritional-metabolic factors implicated in the pathogenesis of CKD.
• To provide insights into potential therapeutic strategies for CKD management.

Main Methods:

• Review of literature on hormonal imbalances, inflammatory markers, and metabolic dysregulations in CKD.
• Analysis of the roles of cytokines, acute-phase proteins, growth hormone-insulin-like growth factor-1 axis, renin-angiotensin aldosterone system (RAAS), adipocytokines, ghrelin, vitamin D, and glucocorticoids in CKD.

Main Results:

• Elevated proinflammatory cytokines (IL-1, IL-6, TNF), altered acute-phase proteins (low albumin, high CRP), and reduced GH/IGF-1 axis activity are observed in CKD.
• Hyperactivation of RAAS contributes to hypertension and insulin resistance; blockade shows reno-protective effects.
• Abnormal adipocytokines, potential ghrelin dysfunction, poor vitamin D status, and increased glucocorticoid activity are implicated in CKD pathogenesis, hypertension, insulin resistance, and cachexia.

Conclusions:

• Multiple interconnected factors, including hormonal, inflammatory, and metabolic disturbances, play crucial roles in CKD development and progression.
• Understanding these factors is essential for improving clinical assessment and developing targeted therapies, including pharmacological, nutritional, and exercise interventions.